Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.25
▼(-24.24% Downside)
Action:UpgradedDate:12/30/25
The score is primarily constrained by weak financial performance—minimal/volatile revenue, continued losses, and ongoing cash burn—partly offset by very low balance-sheet leverage and an improving FY2025 loss/burn profile. Technicals are neutral-to-soft with a negative MACD and price below the 50-day average, and valuation is limited by negative earnings and no dividend support.
Positive Factors
Low leverage / strong liquidity buffer
Extremely low debt reduces refinancing and interest-rate risk, giving management structural flexibility to fund R&D or operations from the balance sheet. Over a 2–6 month horizon this lowers bankruptcy and liquidity risk and supports continuity of strategic programs.
Negative Factors
Minimal and volatile revenue
Very small, inconsistent revenue reflects limited commercial traction and lack of scale. Over months this constrains margin expansion, weakens predictability of cash generation, and increases the probability the firm must rely on dilutive financing to fund ongoing operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong liquidity buffer
Extremely low debt reduces refinancing and interest-rate risk, giving management structural flexibility to fund R&D or operations from the balance sheet. Over a 2–6 month horizon this lowers bankruptcy and liquidity risk and supports continuity of strategic programs.
Read all positive factors
Paradigm Biopharmaceuticals (PAR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$113.45M
Dividend YieldN/A
Average Volume (3M)841.61K
Price to Earnings (P/E)―
Beta (1Y)2.64
Revenue Growth-20.79%
EPS Growth73.98%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding444,908,140
10 Day Avg. Volume720,106
30 Day Avg. Volume841,610
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.53
Price to Sales (P/S)1840.42
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Company Description
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of os...
How the Company Makes Money
null...
Paradigm Biopharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.57K | 52.12K | 65.80K | 46.76K | 79.22K | 20.55K |
| Gross Profit | -97.57K | -19.89K | 56.81K | -18.83K | -64.53K | -78.59K |
| EBITDA | -40.72M | -25.25M | -64.54M | -59.06M | -46.82M | -42.40M |
| Net Income | -36.09M | -18.77M | -58.65M | -51.91M | -39.25M | -34.30M |
Balance Sheet | ||||||
| Total Assets | 23.15M | 24.57M | 27.39M | 67.07M | 50.69M | 84.79M |
| Cash, Cash Equivalents and Short-Term Investments | 14.66M | 16.82M | 17.87M | 56.38M | 39.72M | 71.08M |
| Total Debt | 1.01M | 5.48K | 239.33K | 341.67K | 616.67K | 751.84K |
| Total Liabilities | 17.16M | 3.39M | 3.58M | 13.39M | 8.38M | 6.52M |
| Stockholders Equity | 6.00M | 21.18M | 23.81M | 53.68M | 42.31M | 78.27M |
Cash Flow | ||||||
| Free Cash Flow | -7.77M | -15.99M | -65.94M | -45.19M | -32.21M | -34.96M |
| Operating Cash Flow | -27.42M | -15.99M | -65.94M | -45.19M | -32.21M | -34.93M |
| Investing Cash Flow | -567.20K | 46.20K | 0.00 | 0.00 | 0.00 | 668.37K |
| Financing Cash Flow | 18.17M | 14.99M | 28.18M | 62.53M | 70.12K | 1.00M |
Paradigm Biopharmaceuticals Technical Analysis
Negative
0.33
Price Trends
0.28
Negative
0.31
Negative
0.33
Negative
Market Momentum
>-0.01
Negative
43.27
Neutral
24.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PAR, the sentiment is Negative. The current price of 0.33 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.28, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 24.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PAR.
Paradigm Biopharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$113.45M | -1.51 | -265.55% | ― | -20.79% | 73.98% | |
42 Neutral | AU$56.65M | ― | -254.33% | ― | ― | ― | |
42 Neutral | AU$84.50M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$51.77M | -0.70 | -134.65% | ― | ― | 55.94% | |
41 Neutral | AU$87.00M | -2.12 | -30.19% | ― | ― | 63.46% | |
41 Neutral | AU$137.36M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:PAR
Paradigm Biopharmaceuticals
0.26
-0.08
-22.73%
AU:IMU
Imugene
0.15
-0.94
-86.67%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:NUZ
Pharmaust Limited
0.08
-0.05
-37.01%
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.12
33.43%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-12.50%
Paradigm Biopharmaceuticals Corporate Events
Paradigm Expands Global Phase 3 Osteoarthritis Trial to Hong Kong and Moldova
Mar 19, 2026
Paradigm Biopharmaceuticals has activated a new clinical trial site in Hong Kong for its global Phase 3 study of injectable pentosan polysulfate sodium in patients with knee osteoarthritis, with screening now underway at the Hong Kong Centre for C...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 5.65 Million New Shares
Mar 16, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 5,653,700 new fully paid ordinary shares, with an issue date of March 16, 2026. The issuance of these additional securities expands the company’s quoted share capital, poten...
Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment
Feb 26, 2026
Paradigm Biopharmaceuticals reported a net loss before tax of A$23.2 million for the half-year ended 31 December 2025, a sharp increase from the prior period’s A$5.9 million loss, as it intensified investment in late-stage clinical developme...
Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings
Feb 23, 2026
Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s interests in the company’s securities, detailing movements across fully paid ordinary shares, listed options, performance rights and unlisted piggyback options...
Paradigm Biopharmaceuticals Updates Market on Director Option Lapse
Feb 23, 2026
Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s interests, reporting the lapse of 354,958 listed options exercisable at $0.65 that expired on 11 February 2026. Following the lapse, Fry continues to hold 1,419,830...
Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study
Feb 11, 2026
Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan polysulfate sodium in dogs with naturally occurring osteoarthritis has been published in the peer-reviewed journal PLOS One. The collaborative trial with the Univers...
Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug
Feb 8, 2026
Paradigm Biopharmaceuticals has signed a binding term sheet with AVet Health to co-develop and license an oral combination of pentosan polysulfate sodium and a COX-2 inhibitor for osteoarthritis in companion animals in Australia and New Zealand. A...
Paradigm Biopharmaceuticals Director Converts Options Into Shares
Feb 3, 2026
Paradigm Biopharmaceuticals has disclosed a change in the interests of director Paul Rennie, who has converted 153,265 listed options into fully paid ordinary shares. The transaction, executed on 3 February 2026 for a consideration of $99,622.25, ...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Feb 3, 2026
Paradigm Biopharmaceuticals has applied to the ASX for quotation of 176,880 new ordinary fully paid shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 3 February 2026. The modest ...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Jan 30, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 10,037 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects ...
Paradigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case
Jan 30, 2026
Paradigm Biopharmaceuticals reported continued operational progress in the December 2025 quarter, advancing its global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis pain, with most sites in Australia a...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Jan 27, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 35,544 new ordinary fully paid shares, to be issued on 27 January 2026 following the exercise or conversion of existing options or other convertible securities. The modest share i...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Nearly 5 Million New Shares
Jan 16, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 4,940,912 new fully paid ordinary shares, following the exercise or conversion of options or other convertible securities. The issuance and listing of these additional shares mode...
Paradigm Biopharmaceuticals Flags February 2026 Expiry of 97 Million PAROA Options
Jan 8, 2026
Paradigm Biopharmaceuticals has advised holders of its PAROA quoted options that 97,358,215 options will expire at 5pm AEDT on 11 February 2026, with trading in these options to cease on 5 February 2026. Option holders have been notified that each...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.